These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39093924)

  • 41. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
    Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
    Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
    Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
    Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of
    Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
    J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors.
    Pandrowala SA; Kapoor D; Kunte A; Chopde A; Puranik A; Dev ID; Parghane R; Basu S; Ramaswamy A; Ostwal V; Chaudhari VA; Bhandare MS; Shrikhande SV
    J Gastrointest Cancer; 2024 Sep; 55(3):1220-1228. PubMed ID: 38874852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
    Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
    Ramage J; Naraev BG; Halfdanarson TR
    Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
    [No Abstract]   [Full Text] [Related]  

  • 50. Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity.
    Yasunaga Y; Tanaka M; Arita J; Hasegawa K; Ushiku T
    Hum Pathol; 2024 Aug; 150():51-57. PubMed ID: 38909708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [
    Singh S; Halperin D; Myrehaug S; Herrmann K; Pavel M; Kunz PL; Chasen B; Tafuto S; Lastoria S; Capdevila J; García-Burillo A; Oh DY; Yoo C; Halfdanarson TR; Falk S; Folitar I; Zhang Y; Aimone P; de Herder WW; Ferone D;
    Lancet; 2024 Jun; 403(10446):2807-2817. PubMed ID: 38851203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
    Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
    JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 55. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lutetium [
    Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3417-3427. PubMed ID: 38772998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.
    Katona BW; Roccaro GA; Soulen MC; Yang YX; Bennett BJ; Riff BP; Glynn RA; Wild D; Nicolas GP; Pryma DA; Teitelbaum UR; Metz DC
    Pancreas; 2017 Oct; 46(9):1121-1126. PubMed ID: 28902781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
    Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
    Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.